Trajenta (Linagliptin) is a dipeptidyl peptidase 4 inhibitor (DPP-4) prescribed to treat type 2 diabetes that operates by increasing incretin levels and the amount of insulin released in the body while decreasing the amount of sugar produced by the body.
